CASSAVA- TOPLINE DATA FROM PHASE 3 REFOCUS-ALZ STUDY OF SIMUFILAM IN PATIENTS WITH MILD-TO-MODERATE ALZHEIMER'S DISEASE EXPECTED LATE Q1/EARLY Q2 2025

Reuters · 01/07 21:30

Please log in to view news